

COG-AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

PATIENT ELIGIBILITY:

Important note: The eligibility criteria listed below are interpreted literally and cannot be waived (per COG policy posted 5/11/01). All clinical and laboratory data required for determining eligibility of a patient enrolled on this trial must be available in the patient's medical research record which will serve as the source document for verification at the time of audit.

- ___ 1. **Prior to enrollment on AREN0533 all patients must have been enrolled on AREN03B2 for central pathology review. Stage III patients with LOH transferring from AREN0532 may be enrolled on this study.**
- ___ 2. All Stage IV patients must begin chemotherapy within 14 days of nephrectomy or renal biopsy, unless medically contraindicated or unless central pathological diagnosis requires special studies. In the latter instance, therapy must start within three days of notification of the central pathological diagnosis. Physicians are encouraged not to begin treatment until the central radiology, surgery, and pathology reviews are completed and an initial risk assignment is made on the AREN03B2 study. However, treatment may begin before central review on AREN03B2 is completed if medically indicated (e.g., significant symptoms from large tumor burden), but patients may not enroll on AREN0533 until initial risk assignment occurs.
- ___ 3. Study enrollment must take place within five (5) calendar days of beginning protocol therapy. If enrollment takes place before starting therapy, the date protocol therapy is projected to start is open since there are unforeseen medical complications that may delay a patient's actual start of protocol therapy. However, if the start of protocol therapy is more than five days after enrollment, the medical indication for the delay must be documented in the patient's medical/research record
- ___ 4. For Stage III patients with LOH transferring from AREN0532, patients must be enrolled on this study prior to receiving Week 7 chemotherapy.
- ___ 5. Patients must be less than 30 years of age at the time of diagnosis.
- ___ 6. Prior to enrollment on AREN0533, all patients must have been enrolled on AREN03B2 for central pathology review. Stage III patients with LOH transferring from AREN0532 may be enrolled on this study. Eligible patients for AREN0533 must be:
 - Newly diagnosed Stage IV favorable histology Wilms tumor with or without LOH 1p **and** 16q **or**
 - Newly diagnosed Stage III favorable histology Wilms tumor with LOH for 1p **and** 16q transferring from AREN0532.
- ___ 7. Patients with bilateral Wilms tumors (Stage V) are **not** eligible for AREN0533 and should be directed to AREN0534, once this protocol is open to accrual.
- ___ 8. The Karnofsky performance status must be ≥ 50 for patients >16 years of age and the Lansky performance status must be ≥ 50 for patients ≤ 16 years of age.
- ___ 9. Patients can not have had prior tumor-directed chemotherapy or radiotherapy except for patients transferring from AREN0532.
- ___ 10. Organ Function Requirements:
 - Patients must have adequate liver function defined as:
 - Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and
 - SGOT (AST) or SGPT (ALT) < 2.5 x upper limit of normal (ULN) for age.
 - Patients must have adequate cardiac function defined as:
 - Shortening fraction of $\geq 27\%$ by echocardiogram, or
 - Ejection fraction of $\geq 50\%$ by radionuclide angiogram.
- ___ 11. Female patients of childbearing age must have a negative pregnancy test.
- ___ 12. Female patients who are lactating must agree to stop breast-feeding.
- ___ 13. Sexually active patients of childbearing potential must agree to use effective contraception.

REQUIRED OBSERVATIONS:

Required Clinical, Laboratory and Disease Evaluations

- History
- Physical Exam (Ht, Wt, BSA, VS)
- Performance Status
- CBC, differential, platelets
- Urinalysis
- Electrolytes including Ca⁺⁺, PO₄, Mg⁺⁺
- Creatinine, SGPT, bilirubin
- Total protein/albumin
- CT or MRI of the abdomen and pelvis ¹
- CT chest
- Echocardiogram/EKG

1. Use same modality-CT or MRI- as at the time of diagnosis; for Week 12 Evaluation for all patients and Week 21 for Regimen M patients .

TOXICITIES AND DOSAGE MODIFICATIONS:

See Section 5.0.

SPECIMEN REQUIREMENTS:

Per AREN03B2.

TREATMENT PLAN:
Experimental Design Schema

